Attendee search 

Summary / Data Stingray Therapeutics: Novel Innate Immunity Target - Ectonucleotide Pyrophosphatase / Phosphodiesterase 1 (ENPP1). Stingray Therapeutics, a biotechnology company located in the Texas Medical Center (TMC), is developing next-generation innate immune modulators targeting the STING (Stimulator of Interferon Genes) pathway. Clinical Candidate (SR-8541A) - Potent and Selective Inhibitor of ENPP1 SR-8541A Binds the Catalytic Pocket of ENPP1ENPP1 Inhibitors Activate the STING pathway and Promote Lympocyte Infiltration of Breast Cancer Single-Agent Activity (CT26 - Colon), 57.8% Decrease in Tumor Volume SR-8541A Treatment and Radiation Theapy Demonstrate Synergy and Abscopal Anti-Tumor Response in MC38 Mode Description - STING / ENPP1 The STING pathway is the body’s first level of defense against foreign pathogens (bacteria / viruses) and critical for enabling the adaptive immune system (e.g. T-Cells) to recognize cancer cells and attack. SR-8541A blocks ENPP1’s activity which cancer upregulates to suppress the STING ST imulator of IN terferon G pathway both in cancer cells and in the surrounding tumor microenvironment (TME). By downregulating ENPP1, SR-8541A enhances the innate immune response where adaptive immunity (e.g. checkpoint inhibitors) cannot defeat the cancer alone.SR-8541A used in combination with checkpoint inhibitors enables both arms of the immune system (innate / adaptive) to fight cancer providing a dramatic leap forward in immune-oncology treatment in tumors unresponsive to checkpoint inhibition (prostate , colorectal) and aiding response in tumors where checkpoint inhibitors are currently used melanoma, head and neck, triple-negative breast). Other advantages of ENPP1 inhibition include blocking adenosine production, an important immune suppressor, and helping to block cancer’s ability to repair DNA following targeted and / or chemotherapy. While Stingray's primary focus is oncology, it is also known that activation of the STING pathway via ENPP1 inhibition could have a major impact in infectious diseases, including Mycobacterium Tuberculosis and Hepatitis B, through the stimulation of host defense immunity. Timeline: Pre-IND Enabling Studies: 3Q2020 - 1Q2020 GLP Toxicology Single-Agent Pre-Clinical Studies (interferon responsive tumors - CTCL, Myelofibrosis and immune responsive tumors) Combination Studies - checkpoint inhibitors, anti-CD38 in multiple myeloma, PRRT (liquid radiation), PARP inhibitors, chemotherapy, CAR-T / CAR-NK cells File IND - 1Q2020 Financing: Stingray is raising $1.5M of bridge financing (convertible note funding pre-IND studies) leading to a $15M Series A advancing the company’s lead small molecule compound, SR-8541A, through Phase 1 clinical studies. Use of Proceeds $1M: Pre-Clinical (Chemistry, Biology, CMC, Toxicology) $1M: IP, Legal $11M: Two (2) Phase 1 Clinical Studies $2M: Administration